Why Shares of Moderna, Novavax, and Ocugen Are Falling Today
Most COVID-19 vaccine stocks are having a terrible end to the week. Shares of Moderna (NASDAQ: MRNA) are off by 3.4%; Novavax (NASDAQ: NVAX) is down 5.1%; and Ocugen's (NASDAQ: OCGN) stock is in the red by a jaw-dropping 13.3%, all as of 3:34 p.m. EDT Friday.
While it might be easy to blame the possibility of forthcoming home treatments for moderate COVID-19 cases for this across-the-board drop, the real reason(s) are likely more complex. The U.S. Food and Drug Administration (FDA) might delay the decision on Moderna's jab for adolescents due to safety issues, according to a report from the Wall Street Journal. Novavax's COVID-19 vaccine continues to fall behind the leaders in the space -- possibly knocking down its peak sales by a significant amount. And Ocugen, through its Indian partner, has yet to hear from either the World Health Organization or the FDA about their vaccine candidate.
Image source: Getty Images.
Source Fool.com
